Hepatitis C virus and lymphoma

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 3, 2015, Pages 246-256

  Paydas, Semra ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Aggressive indolent lymphoma; HCV; HCV prognostic score; Lymphoma; Rituximab, Immuno chemotherapy; Sustained viral response

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PROTEIN BAX; PROTEIN BCL 2; RIBAVIRIN; RITUXIMAB; VIRUS RNA; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GRADING; CARCINOGENESIS; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; GENETIC SUSCEPTIBILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MUTAGENESIS; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; VIRUS TRANSMISSION; COMPLICATION; DISEASE MANAGEMENT; GENETICS; GENOTYPE; HEPACIVIRUS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MORTALITY; PREVALENCE; RISK; TRANSMISSION; TREATMENT OUTCOME; VIROLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DISEASE MANAGEMENT; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; PREVALENCE; RISK; TREATMENT OUTCOME;

EID: 84922424021     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.10.008     Document Type: Review

References (100)

1. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
2. Durand T., Di Liberto G., Colman H., et al. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 2010, 59:934-942.
3. Peveling-Oberhag J., Arcaini L., Hansmann M.L., Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013, 59:169-177.
4. Zignego A.L., Giannini C., Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007, 13:2467-2478.
5. Simonetti R.G., Camma C., Fiorello F., et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992, 116:97-102.
6. Misiani R., Bellavita P., Fenili D., et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992, 117:573-577.
7. Ferri C., Greco F., Longombardo G., et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991, 9:621-624.
8. Zignego A.L., Ferri C., Giannini C., et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 1997, 142:545-555.
9. Hartridge-Lambert S.K., Stein E.M., Markowitz A.J., Portlock C.S. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012, 55:634-641.
10. Ferri C., La Civita L., Caracciolo F., Zignego A.L. Non-Hodgkin's lymphoma: possible role of hepatitis C virus. JAMA 1994, 272:355-356.
11. Negri E., Little D., Boicchi M., Vecchia C.L.A., Franceschi S. B-cell non-Hodgkin's lymphoma hepatitis C virus infection: a systematic review. Int Cancer J 2004, 111:1-8.
12. Nieters A., Kallinowski B., Brennan P., et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006, 131:1879-1886.
13. Pozzato G., Mazzaro C., Crovatto M., et al. Lowgrade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994, 84:3047-3053.
14. Ferri C., Caracciolo F., Zignego A.L., et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994, 88:392-394.
15. Mele A., Pulsoni A., Bianco E., et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102:996-999.
16. Duberg A.-S., Nordstrom M., Torner A., et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005, 41:652-659.
17. Anderson L.A., Pfeiffer R., Warren J.L., et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008, 17:3069-3075.
18. Gisbert J.P., García-Buey L., Pajares J.M., Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003, 125:1723-1732.
19. Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins. J Clin Pathol 2002, 55:4-13.
20. Monti G., Pioltelli P., Saccardo F., et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005, 165:101-105.
21. Landau D.A., Saadoun D., Halfon P., et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008, 58:604-611.
22. Talamini R., Montella M., Crovatto M., et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004, 110:380-385.
23. Morton L.M., Engels E.A., Holford T.R., et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev 2004, 13:425-430.
24. Goldman L., Ezzat S., Mokhtar N., et al. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 2009, 20:981-987.
25. Sch€ollkopf C., Smedby K.E., Hjalgrim H., et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008, 122:1885-1890.
26. Omland L.H., Jepsen P., Krarup H., et al. Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study. Int J Cancer 2012, 130:2310-2317.
27. Cocco P., Piras G., Monne M., et al. Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 2008, 87:474-483.
28. Mizorogi F., Hiramoto J., Nozato A., et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Intern Med 2000, 39:112-117.
29. Sy T., Jamal M.M. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:41-46.
30. Pellicelli A.M., Marignani M., Zoli V., et al. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World J Hepatol 2011, 3(11):278-284.
31. Franzin F., Efremov D.G., Pozzato G., Tulissi P., Batista F., Burrone O.R. Clonal B-cell expansions in peripheral blood of HCV infected patients. Br J Haematol 1995, 90:548-552.
32. Matsuo K., Kusano A., Sugumar A., Nakamura S., Tajima K., Mueller N.E. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004, 95:745-752.
33. Dal Maso L., Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006, 15:2078-2085.
34. de Sanjose S., Benavente Y., Vajdic C.M., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008, 6:451-458.
35. Forghieri F., Luppi M., Barozzi P., et al. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol 2012, 1-9. [Article ID 807351].
36. Morton L.M., Gibson T.M., Clarke C.A., Lynch C.F., Weisenburger D.D., Engels E.A. Hepatitis B or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant recipients. Haematologica 2014, 99:70-73.
37. Mazzaro C., Zagonel V., Monfardini S., et al. Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol 1996, 94:544-550.
38. Paydas S., Kiliç B., Sahin B., Bugdayci R. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. Br J Cancer 1999, 80:1303-1305.
39. Paydas S., Kilic B., Yavuz S., et al. Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin's lymphoma. Am J Hematol 2003, 74:89-93.
40. Greeve J., Philipsen A., Krause K., et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003, 101:3574-3580.
41. Agematsu K., Hokibara S., Nagumo H., Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000, 21:204-206.
42. Mizuochi T., Ito M., Saito K., et al. Possible recruitment of peripheral blood CXCR3+ CD27+ CD19+ B cells to the liver of chronic hepatitis C patients. J Interferon Cytokine Res 2010, 30:243-252.
43. Pal S., Sullivan D.G., Kim S., et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 2006, 130:1107-1116.
44. Paydas S., Ergin M., Tanriverdi K., et al. Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma. Am J Hematol 2004, 76:252-257.
45. Engels E.A., Chatterjee N., Cerhan J.R., et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004, 111:76-80.
46. Ferri C., La Civita L., Zignego A.L., Pasero G. Viruses and cancers: possible role of hepatitis C virus. Eur J Clin Invest 1997, 27:711-718.
47. Silvestri F., Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol 1997, 99:475-480.
48. Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48:148-162.
49. Stolte M., Bayerdorffer E., Morgner A., et al. Helicobacter and gastric MALT lymphoma. Gut 2002, 50(Suppl. 3):19-24.
50. Hermine O., Lefrère F., Bronowicki J.P., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89-94.
51. Vallisa D., Bernuzzi P., Arcaini L., et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005, 23:468-473.
52. Arcaini L., Vallisa D., Merli M. Hematological response to antiviral therapy in 94 patients with indolent B-cell lymphomas associated with hepatitis C virus infection: a study of the Fondazione Italiana Linfomi (FIL). Ann Oncol 2011, 22:128-129. [Lugano Meeting Abstract no. 138].
53. Zignego A.L., Macchia D., Monti M., et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepat 1992, 15:382-386.
54. Ferri C., Monti M., La Civita L., et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993, 82:3701-3704.
55. Ito M., Kusunoki H., Mochida K., Yamaguchi K., Mizuochi T. HCV infection and B-cell lymphomagenesis. Adv Hemat 2011, 1-8. ID 835314.
56. Zignego A.L., Giannini C., Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012, 1-8. ID 980942.
57. Galli M., Zehender G., Monti G., et al. Hepatitis C virus RNA in the bone marrow of patients with mixed cryoglobulinemia and in subjects with noncryoglobulinemic chronic hepatitis type C. J Infect Dis 1995, 171:672-675.
58. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
59. Rosa D., Saletti G., De Gregorio E., et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. PNAS 2005, 102:18544-18549.
60. Machida K., Cheng K.T., Sung V.M., et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci 2004, 101:4262-4267.
61. Ito M., Murakami K., Suzuki T., et al. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 2010, 135:459-465.
62. Tsukiyama-Kohara K., Sekiguchi S., Kasama Y., Salem N.E., Machida K., Kohara M. Hepatitis C virus-related lymphomagenesis in a mouse model. ISRN Hematol 2011, 1-8. [Article ID 167501].
63. Silvestri F., Barillari G., Fanin R., et al. The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. Leukemia 1997, 11:2157-2161.
64. Luppi M., Grazia Ferrari M., Bonaccorsi G., et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 1996, 10:351-355.
65. De Rosa G., Gobbo M.L., De Renzo A., et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol 1997, 55:77-82.
66. Pioltelli P., Gargantini L., Cassi E., et al. Hepatitis C virus in non-Hodgkin's lymphoma. A reappraisal after a prospective case-control study of 300 patients. Lombart Study Group of HCV-Lymphoma. Am J Hematol 2000, 64:95-100.
67. Kasama Y., Sekiguchi S., Saito M., et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010, 116:4926-4933.
68. Giannelli F., Moscarella S., Giannini C., et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003, 102:1196-1201.
69. Goldberg-Bittman L., Kitay-Cohen L., Hadari R., Yukla M., Fejgin M.D., Amiel A. Random aneuploidy in chronic hepatitis C patients. Cancer Genet Cytogenet 2008, 180:20-23.
70. Machida K., Liu J.C., McNamara G., Levine A., Duan L., Lai M.M.C. Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J Virol 2009, 83:12590-12600.
71. De Vita S., Quartuccio L., Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?. Autoimmun Rev 2008, 8:95-99.
72. Ng P.P., Kuo C.C., Wang S., et al. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 2014, 123:1512-1515.
73. Kasama Y., Mizukami T., Kusunoki H., et al. B-cell-intrinsic hepatitis C virus expression leads to B-cell-lymphomagenesis and induction of NF-Kb signalling. PLOS ONE 2014, 9:1-11.
74. Augello C., Gianelli U., Savi F., et al. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. J Clin Pathol 2014, 67:697-701.
75. Sansonno D., De Vita S., Iacobelli A.R., Cornacchiulo V., Boiocchi M., Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998, 160:3594-3601.
76. Sansonno D., Lauletta G., De Re V., et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004, 34:126-136.
77. Libra M., Polesel J., Russo A.E., et al. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia?. Int J Oncol 2010, 36:1331-1340.
78. Visco C., Arcaini L., Brusamolino E., et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006, 17:1434-1440.
79. Park B.B., Kim J.S., Lee Y.Y., et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma 2008, 49:88-94.
80. Strianese D., Tranfa F., Finelli M., et al. Hepatitis C virus infection in ocular adnexal lymphomas. Arch Ophthalmol 2010, 128:1295-1299.
81. Besson C., Canioni D., Lepage E., et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C viruspositive patients in LNH 93 and LNH 98 groupe d'etude des lymphomes de l'adulte programs. J Clin Oncol 2006, 24:953-960.
82. Ennishi D., Maeda Y., Niitsu N., et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010, 116:5119-5125.
83. Torres H.A., Nevah M.I., Barnett B.J., et al. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study. J Clin Virol 2012, 54(3):218-222.
84. Luppi M., Ferrari M.G., Torelli G. Hepatitis C virus genotype distribution in B-cell non-Hodgkin lymphoma. Ann Int Med 1998, 128:602.
85. Kawamura Y., Ikeda K., Arase Y., et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007, 120:1034-1041.
86. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
87. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
88. Pawlotsky J. The results of phase III clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011, 140:746-754.
89. Gisbert J.P., Garćia-Buey L., Pajares J.M., Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Alim Pharmacol Ther 2005, 21:653-662.
90. Arcaini L., Vallisa D., Rattotti S., et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014, 25:1404-1410.
91. La Mura V., De Renzo A., Perna F., et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol 2008, 49:557-563.
92. Tomita N., Kodama F., Takabayashi M., et al. Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003, 44:1159-1164.
93. Nooka A., Shenoy P.J., Sinha R., Lonial S., Flowers C.R. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leukemia 2011, 11:379-384.
94. Cox M.C., Aloe-Spiriti M.A., Cavalieri E. HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: evidence and open questions. World J Gastrointest Oncol 2012, 15:46-53.
95. Merli M., Visco C., Spina M., et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2013, 99:489-496.
96. Arcaini L., Merli M., Passamonti F., et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 2010, 85:46-50.
97. Marignani M., Mangone M., Cox M.C., et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011, 43:139-142.
98. Nishikawa H., Tsudo M., Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep 2012, 28:835-840.
99. Zaky A.H., Bakry R., El-Sayed M.I., Elwanis M.A., Nabih O. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology 2014, 20. [Epub ahead of print].
100. Salah-Eldin M.A., Ebrahim M.A., El-Sadda W. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. Ann Hematol 2014, [published online 21 June].